^
    over1year
    Good teaching case from @BloodJournal Images in #Hematology that (1) not all M-spikes are myeloma, (2) not all lymphoplasmacytic lymphomas are IgM isotype, and (3) remember to request MYD88 and CXCR4 mutations in this setting. #mmsm https://t.co/OpVazjbeNA (@docbraunstein)
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    CXCR4 mutation • MYD88 mutation + CXCR4 mutation
    over2years
    Congratulations David and @fdezdelarrea for the excellent study on MYD88 and CXCR4 mutations in IgM MGUS and smoldering WM! Challenge accepted, we will try to improve the sensitivity of #flowcytometry to detect Waldenström's clonal cells! #ASH21 #mmsm (@BrunoPaiva_UNAV)
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    CXCR4 mutation • MYD88 mutation + CXCR4 mutation
    over2years
    Venetoclax in Previously Treated Waldenström Macroglobulinemia ⁦@JCO_ASCO⁩ 👉🏻 ORR84%👉🏻CXCR4 mutations did not affect treatment response or progression-free survival #mmsm | Journal of Clinical Oncology https://t.co/jDzNGbOCPS (@SLentzsch)
    Clinical
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    CXCR4 mutation
    |
    Venclexta (venetoclax)
    over2years
    IgM Plasma Cell Myeloma: Clinicopathologic Features Including Evaluation for MYD88 and CXCR4 Mutations https://t.co/HnYycjhKQj #mmsm #medEd #medtwitter (@Abdallah81MD)
    Clinical
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    CXCR4 mutation • MYD88 mutation + CXCR4 mutation
    over2years
    Recently,[Dale. Blood. 2020] showed the CXCR4 inhibitor mavorixafor can increase circulating PMNs and decrease infections in WHIM patients. Interestingly, the same CXCR4 mutation in WHIM is seen in Waldenstrom macroglobulinemia and is associated with worse responses to ibrutinib (@AaronGoodman33)
    Clinical
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    CXCR4 mutation
    |
    Imbruvica (ibrutinib) • mavorixafor (X4P-001)